Whole-exome sequencing reanalysis at 12 months boosts diagnosis and is cost-effective when applied early in Mendelian disorders

PurposeWhole-exome sequencing (WES) has revolutionized Mendelian diagnostics, however, there is no consensus on the timing of data review in undiagnosed individuals and only preliminary data on the cost-effectiveness of this technology. We aimed to assess the utility of WES data reanalysis for diagnosis in Mendelian disorders and to analyze the cost-effectiveness of this technology compared with a traditional diagnostic pathway.MethodsWES was applied to a cohort of 54 patients from 37 families with a variety of Mendelian disorders to identify the genetic etiology. Reanalysis was performed after 12 months with an improved WES diagnostic pipeline. A comparison was made between costs of a modeled WES pathway and a traditional diagnostic pathway in a cohort with intellectual disability (ID).ResultsReanalysis of WES data at 12 months improved diagnostic success from 30 to 41% due to interim publication of disease genes, expanded phenotype data from referrer, and an improved bioinformatics pipeline. Cost analysis on the ID cohort showed average cost savings of US$586 (AU$782) for each additional diagnosis.ConclusionEarly application of WES in Mendelian disorders is cost-effective and reanalysis of an undiagnosed individual at a 12-month time point increases total diagnoses by 11%.

[1]  Karin S Kassahn,et al.  Integrating Massively Parallel Sequencing into Diagnostic Workflows and Managing the Annotation and Clinical Interpretation Challenge , 2014, Human mutation.

[2]  Michael J Ackerman,et al.  Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic: The Mayo Clinic Experience. , 2016, Mayo Clinic proceedings.

[3]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[4]  Xuan Yuan,et al.  Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders , 2014, Science Translational Medicine.

[5]  Mustafa Tekin,et al.  The promise of whole-exome sequencing in medical genetics , 2013, Journal of Human Genetics.

[6]  J. Shendure,et al.  Exome sequencing as a tool for Mendelian disease gene discovery , 2011, Nature Reviews Genetics.

[7]  Christian Gilissen,et al.  Unlocking Mendelian disease using exome sequencing , 2011, Genome Biology.

[8]  Michael F. Wangler,et al.  Lessons learned from additional research analyses of unsolved clinical exome cases , 2017, Genome Medicine.

[9]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[10]  Wilko Spiering,et al.  Diagnostic Clinical Genome and Exome Sequencing , 2014 .

[11]  L. Vissers,et al.  Genome sequencing identifies major causes of severe intellectual disability , 2014, Nature.

[12]  W. Chung,et al.  Clinical application of whole-exome sequencing across clinical indications , 2015, Genetics in Medicine.

[13]  Eric Vilain,et al.  Clinical exome sequencing for genetic identification of rare Mendelian disorders. , 2014, JAMA.

[14]  Xuejun Zhang.  Exome sequencing greatly expedites the progressive research of Mendelian diseases , 2014, Frontiers of Medicine.

[15]  Eric Legius,et al.  Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation , 2008, Human mutation.

[16]  Yongwook Choi,et al.  PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels , 2015, Bioinform..

[17]  C. Doran,et al.  How much does intellectual disability really cost? First estimates for Australia , 2012, Journal of intellectual & developmental disability.

[18]  Ituro Inoue,et al.  Next-generation sequencing: impact of exome sequencing in characterizing Mendelian disorders , 2012, Journal of Human Genetics.

[19]  R. Durbin,et al.  Bi-allelic Truncating Mutations in TANGO2 Cause Infancy-Onset Recurrent Metabolic Crises with Encephalocardiomyopathy. , 2016, American Journal of Human Genetics.

[20]  Clara Gaff,et al.  Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement , 2017, Genetics in Medicine.

[21]  Aaron R. Quinlan,et al.  GEMINI: Integrative Exploration of Genetic Variation and Genome Annotations , 2013, PLoS Comput. Biol..

[22]  Saskia B Wortmann,et al.  Mitochondrial dysfunction and organic aciduria in five patients carrying mutations in the Ras-MAPK pathway , 2011, European Journal of Human Genetics.

[23]  B. Fernandez,et al.  Utility of whole‐exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care , 2015, Clinical genetics.

[24]  Magalie S Leduc,et al.  Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.

[25]  J. Casanova,et al.  Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants , 2014, Proceedings of the National Academy of Sciences.

[26]  I. Tikhonova,et al.  Genetic diagnosis by whole exome capture and massively parallel DNA sequencing , 2009, Proceedings of the National Academy of Sciences.

[27]  Peter Nürnberg,et al.  HomozygosityMapper—an interactive approach to homozygosity mapping , 2009, Nucleic Acids Res..

[28]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[29]  Mahshid S. Azamian,et al.  Recurrent Muscle Weakness with Rhabdomyolysis, Metabolic Crises, and Cardiac Arrhythmia Due to Bi-allelic TANGO2 Mutations. , 2016, American journal of human genetics.

[30]  K. Xia,et al.  Exome sequencing released a case of X-linked adrenoleukodystrophy mimicking recessive hereditary spastic paraplegia. , 2013, European journal of medical genetics.

[31]  J. Majewski,et al.  A new ocular phenotype associated with an unexpected but known systemic disorder and mutation: novel use of genomic diagnostics and exome sequencing , 2011, Journal of Medical Genetics.

[32]  Jeremy M. Harris,et al.  Genomics in Clinical Practice: Lessons from the Front Lines , 2013, Science Translational Medicine.

[33]  Allyn McConkie-Rosell,et al.  The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders , 2013, Genetics in Medicine.

[34]  N. Rahman,et al.  Mutations in the PP2A regulatory subunit B family genes PPP2R5B, PPP2R5C and PPP2R5D cause human overgrowth , 2015, Human molecular genetics.

[35]  Xiang Li,et al.  Enhanced utility of family-centered diagnostic exome sequencing with inheritance model–based analysis: results from 500 unselected families with undiagnosed genetic conditions , 2014, Genetics in Medicine.

[36]  G. Bejerano,et al.  Systematic reanalysis of clinical exome data yields additional diagnoses: implications for providers , 2016, Genetics in Medicine.